ABUS vs SPCE · P/E 5.4, rev $6.2M vs rev $7.0M
Arbutus Biopharma Corp (ABUS) versus Virgin Galactic Holdings Inc (SPCE) — a side-by-side from cached financials, not a winner call.
Arbutus Biopharma Corp (ABUS) is a biotechnology company listed on NASDAQ.
Virgin Galactic Holdings Inc (SPCE) is a aerospace & defense company listed on NYSE.
Latest reported ABUS revenue for 2024-12-31 was $6.2M. Net income was -$69.9M. Revenue was down 66.0% from 2023-12-31 to 2024-12-31. ABUS currently screens at market cap $883.0M and trailing P/E 5.4.
Latest reported SPCE revenue for 2024-12-31 was $7.0M. Net income was -$346.7M. Revenue was up 3.5% from 2023-12-31 to 2024-12-31. SPCE currently screens at market cap $388.0M.
ABUS currently screens at market cap $883.0M and trailing P/E 5.4. SPCE currently screens at market cap $388.0M.
Not investment advice. Open the ABUS and SPCE stock pages for the full models.
Not investment advice.